The facility is a boost for the state’s production capabilities, which were under the spotlight last month when the Massachusetts Biotechnology Council (MBC) said the region is struggling to attract the manufacturing sector.
Completion of the facility will give WLI the capacity to provide aseptic fill/finish manufacturing to client producing therapeutics for preclinical development and clinical trials.
Janet Wolfe, president and founder of Wolfe Laboratories, said: "These funds will allow us to expand our capabilities, which our clients have been requesting, so that we can rapidly provide high quality IND-enabling drug development and manufacturing services to contribute to a sustainable drug pipeline."
WLI is constructing the facility to provide clients with integrated development and manufacturing services, which removes the risks and delays associated with transferring technologies.
Mass fund helps 7 businesses
The loan given to WLI is one of seven given to early stage companies, which form the first phase of distributing the states $1bn life science fund. A total of $3.4m was given to the companies, which were selected from 88 applicants.
Representative Peter Koutoujian said: “The Accelerator Program loans are a stabilising resource in such uncertain economic times, especially for pioneering companies like Wolfe Laboratories doing important research necessary in the drug development process.
“It is important to promote early-stage companies such as Wolfe because they not only bring business into our cities and towns, but also save and improve lives through their research."